Table 1 Clinicopathological characteristics of patients with SMIHigh and SMILow UGC
All patients (n = 83) | SMIHigh (n = 41) | SMILow (n = 42) | p value | |
|---|---|---|---|---|
Age (years) | 65.4 ± 12.4 | 64.9 ± 14.5 | 67.9 ± 9.2 | 0.176 |
Sex | 0.119 | |||
 Male | 61 (73.5) | 27 (65.9) | 34 (81.0) | |
 Female | 22 (26.5) | 14 (34.1) | 8 (19.0) | |
ECOG PS (0/1/2) | 0.209 | |||
 0 | 41 (49.4) | 24 (58.5) | 17 (40.5) | |
 1 | 38 (45.8) | 16 (39.0) | 22 (52.4) | |
 2 | 4 (4.8) | 1 (2.5) | 3 (7.1) | |
BMI | 20.0 ± 3.8 | 21.5 ± 4.3 | 18.6 ± 2.5 | < 0.001 |
SMI | 42.8 ± 7.7 | 47.4 ± 7.3 | 38.2 ± 5.0 | < 0.001 |
Unresectable cause | 0.907 | |||
 Advanced cases | 39 (47.0) | 19 (46.3) | 20 (47.6) | |
 Recurrent cases | 44 (53.0) | 22 (53.7) | 22 (52.4) | |
Histologic type | 0.222 | |||
 Differentiated | 38 (45.8) | 16 (39.0) | 22 (52.4) | |
 Undifferentiated | 45 (54.2) | 25 (61.0) | 20 (47.6) | |
Peritoneum metastases | 0.903 | |||
 Positive | 37 (44.6) | 18 (43.9) | 19 (45.2) | |
 Negative | 46 (55.4) | 23 (56.1) | 23 (54.8) | |
Lymph node metastases | 0.898 | |||
 Positive | 35 (42.2) | 17 (41.5) | 18 (42.9) | |
 Negative | 48 (57.8) | 24 (58.5) | 24 (57.1) | |
Hematogenous metastases | 0.867 | |||
 Positive | 25 (30.1) | 12 (29.3) | 13 (31.0) | |
 Negative | 58 (69.9) | 29 (70.7) | 29 (69.0) | |
Lines of chemotherapy | 0.289 | |||
  < 2nd line | 16 (19.3) | 6 (14.6) | 10 (23.8) | |
 ≧2nd line | 67 (80.7) | 35 (85.4) | 32 (76.2) | |
Lines of chemotherapy | ||||
  < 3rd line | 42 (50.6) | 16 (39.0) | 26 (61.9) | 0.037 |
 ≧3rd line | 41 (49.4) | 25 (61.0) | 16 (38.1) |